Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations
Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations
复制标题
DOI：
10.1016/j.clim.2014.02.001
复制
发表时间：
2014-04-01
影响因子：
8.6
通讯作者：
Kikuchi, Seiji
中科院分区：
文献类型：
--
作者：
Miyazaki, Yusei;Niino, Masaaki;Kikuchi, Seiji
芬戈莫德治疗多发性硬化症（MS）的主要机制被认为是将致病淋巴细胞隔离到次级淋巴组织中。B细胞最近被认为是MS中重要的免疫调节因子，本研究分析了芬戈莫德对MS患者B细胞的影响。接受fingolimod （MS- f）治疗的MS患者血液循环中的B细胞数量明显降低。MS-F患者血液中剩余的B细胞中记忆B细胞比例减少，幼稚B细胞比例增加，共刺激分子CD80表达水平降低，肿瘤坏死因子-a分泌较少，白细胞介素-10分泌较多。MS-F中的这些观察结果是基于初始b细胞区内移行性b细胞亚群比例的增加。MS-F B细胞中观察到的结果可能与该药治疗ms的疗效有关(c) 2014 Elsevier Inc.。版权所有。
The chief therapeutic mechanism of fingolimod in multiple sclerosis (MS) is considered to be sequestration of pathogenic lymphocytes into secondary lymphoid tissues. B cells have recently been recognized as important immune regulators in MS. In this study, the effects of fingolimod on B cells in MS patients were analyzed. MS patients treated with fingolimod (MS-F) had a significantly lower number of B cells in the circulation. The remaining B cells in the blood of MS-F had a reduced proportion of memory B cells and an increased proportion of naive B cells, expressed lower levels of the costimulatory molecule CD80, and produced less tumor necrosis factor-a and more interleukin-10. These observations in MS-F were based on an increased proportion of the transitional B-cell subpopulation within the na ve B-cell compartment. The observed findings in B cells of MS-F might be related to the therapeutic effect of this drug in MS. (c) 2014 Elsevier Inc. All rights reserved.